MediWound Ltd. (MDWD)

NASDAQ: MDWD · IEX Real-Time Price · USD
8.90
-0.20 (-2.20%)
At close: Dec 6, 2023, 4:00 PM
8.98
+0.08 (0.90%)
After-hours: Dec 6, 2023, 4:02 PM EST
-2.20%
Market Cap 82.47M
Revenue (ttm) 24.97M
Net Income (ttm) -12.43M
Shares Out 9.21M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,056
Open 9.00
Previous Close 9.10
Day's Range 8.90 - 9.11
52-Week Range 7.10 - 14.58
Beta 1.05
Analysts Strong Buy
Price Target 28.00 (+214.61%)
Earnings Date Nov 21, 2023

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other ha... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 20, 2014
Employees 83
Stock Exchange NASDAQ
Ticker Symbol MDWD
Full Company Profile

Financial Performance

In 2022, MediWound's revenue was $26.50 million, an increase of 11.50% compared to the previous year's $23.76 million. Losses were -$19.60 million, 44.6% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for MDWD stock is "Strong Buy." The 12-month stock price forecast is $28.0, which is an increase of 214.61% from the latest price.

Price Target
$28.0
(214.61% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand

16 days ago - GlobeNewsWire

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today ...

16 days ago - GlobeNewsWire

MediWound to Report Third Quarter 2023 Financial Results

Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time

23 days ago - GlobeNewsWire

MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

The label expansion will solidify NexoBrid's position in the EU as a safe and effective non-surgical treatment for burn patients of all ages The label expansion will solidify NexoBrid's position in th...

24 days ago - GlobeNewsWire

MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

NexoBrid complements PMI's portfolio, allowing it to provide a comprehensive solution for burn patients NexoBrid complements PMI's portfolio, allowing it to provide a comprehensive solution for burn p...

4 weeks ago - GlobeNewsWire

MediWound Announces Collaboration with 3M on EscharEx® Phase III Study

MediWound to join forces with 3M Health Care, world's largest wound care company in pivotal study for patients with venous leg ulcers MediWound to join forces with 3M Health Care, world's largest woun...

2 months ago - GlobeNewsWire

MediWound Deploys NexoBrid® for Emergency Supply

YAVNE, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, addres...

2 months ago - GlobeNewsWire

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

R&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution R&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solut...

2 months ago - GlobeNewsWire

MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Full commercia...

2 months ago - GlobeNewsWire

MediWound's NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress

YAVNE, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue...

3 months ago - GlobeNewsWire

MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference

YAVNE, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today...

3 months ago - GlobeNewsWire

MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

EscharEx ® Phase III study protocol : FDA/EM A-aligned ; p atient enrollment commencing early 2024 ; two key research collaborations with wound industry leaders

4 months ago - GlobeNewsWire

MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study

MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers MediWound joins forces with one of the largest global chronic wound c...

4 months ago - GlobeNewsWire

MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study

MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers MediWound to join forces with leading chronic wound allograft company in pivo...

4 months ago - GlobeNewsWire

MediWound to Report Second Quarter 2023 Financial Results

Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time

4 months ago - GlobeNewsWire

MediWound Announces Commercial Launch of NexoBrid® in Japan

Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement

4 months ago - GlobeNewsWire

MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

MW005 shown to be safe and well-tolerated Data provide clinical efficacy proof-of-concept based on clearance of target lesions YAVNE, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: ...

5 months ago - GlobeNewsWire

MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design

Affirms the clear path forward for the Company's global Phase III study of EscharEx in venous leg ulcers Affirms the clear path forward for the Company's global Phase III study of EscharEx in venous l...

5 months ago - GlobeNewsWire

MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023

YAVNE, Israel, June 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today ...

6 months ago - GlobeNewsWire

MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update

On track to initiate EscharEx ® Phase III study in fourth quarter 2023 NexoBrid ® U.S. launch expected in early third quarter 2023 Cash of over $57 million; Operating cash runway through profitability

6 months ago - GlobeNewsWire

MediWound to Report First Quarter 2023 Financial Results

Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time

7 months ago - GlobeNewsWire

MediWound Announces an Additional $10 Million Award from BARDA

Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension Funding to support emergency stockpiling replenishment, pediat...

7 months ago - GlobeNewsWire

MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023

Data to be highlighted in oral and poster presentations YAVNE, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-ge...

8 months ago - GlobeNewsWire

MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update

2022 total revenues of $26.5 million

9 months ago - GlobeNewsWire

MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer

YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair...

9 months ago - GlobeNewsWire